Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Biochemical and Biophysical Research Communications|April 10, 2019
Trypanosoma cruzi actins: Expression analysis of actin 2Andrea Vizcaíno-Castillo, Juan Felipe Osorio-Méndez, Margarita Rubio-Ortiz, et al.
Emerging Infectious Diseases|May 8, 2007
Host-associated genetic import in Campylobacter jejuniNoel D McCarthy, Frances M Colles, Kate E Dingle, et al.
Infection and Immunity|April 18, 2012
Cj1136 is required for lipooligosaccharide biosynthesis, hyperinvasion, and chick colonization by Campylobacter jejuniMuhammad Afzal Javed, Shaun A Cawthraw, Abiyad Baig, et al.
BMJ Open|September 21, 2023
Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference studyLara Philipps, Stephanie Foster, Deborah Gardiner, et al.
Acta Tropica|July 29, 2026
Assessment of Trypanosoma cruzi Seroprevalence and Diagnostic Evolution in Mexican Blood Banks: A Systematic ReviewCarmen Guzmán-Bracho, Aracely López-Monteon, Anahí Sosa-Arroniz, et al.
Plos One|September 25, 2010
Genomic characterization of Campylobacter jejuni strain M1Carsten Friis, Trudy M Wassenaar, Muhammad A Javed, et al.
Research Involvement and Engagement|July 2, 2025
Patient and public involvement in the SPRUCE methodology study investigating electronic patient reported outcomes in oncology clinical trialsMorgaine Stiles, Monisha Dewan, Georgina Manning, et al.
European Urology|September 12, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised TrialNicholas van As, Binnaz Yasar, Clare Griffin, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2025
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapySian Cooper, Rosalyne L Westley, Katie Biscombe, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
Pageof 4